Systematic review and meta‐analysis: levofloxacin‐based rescue regimens after <i>Helicobacter pylori</i> treatment failure

Gisbert, Javier P.; Morena, Felipe de la

doi:10.1111/j.1365-2036.2006.02737.x

Cited by 288 publications

(284 citation statements)

References 38 publications

Supporting

Mentioning

256

Contrasting

Unclassified

Order By: Relevance

“…3,4 Our success rate, however, is significantly higher compared to their results. It would be pertinent to know the current level of resistance to levofloxacin in Spain.…”

contrasting

confidence: 50%

Letter: third‐line rescue therapy with levofloxacin after failure of two treatments to eradicate Helicobacter pylori infection – author's reply

Goh

2012

Aliment Pharmacol Ther

View full text Add to dashboard Cite

“…3,4 Our success rate, however, is significantly higher compared to their results. It would be pertinent to know the current level of resistance to levofloxacin in Spain.…”

contrasting

confidence: 50%

Letter: third‐line rescue therapy with levofloxacin after failure of two treatments to eradicate Helicobacter pylori infection – author's reply

Goh

2012

Aliment Pharmacol Ther

View full text Add to dashboard Cite

“…Three meta-analysis confirm that associating a standard dose of proton pump inhibitor, twice a day, amoxicillin 1.0 g twice a day and levofloxacin 500 mg once daily for 10 days achieves eradication rates of around 80% (74,122,179) . Although widely used in Brazil there are no validation studies among us.…”

Section: Statement 30mentioning

confidence: 79%

3rd BRAZILIAN CONSENSUS ON Helicobacter pylori

Coelho

Maguinilk

Zaterka³

et al. 2013

Arq. Gastroenterol.

View full text Add to dashboard Cite

Significant progress has been obtained since the Second Brazilian Consensus Conference on Helicobacter pylori Infection held in 2004, in São Paulo, SP, Brazil, and justify a third meeting to establish updated guidelines on the current management of H. pylori infection. The Third Brazilian Consensus Conference on H pylori Infection was organized by the Brazilian Nucleus for the Study of Helicobacter, a Department of the Brazilian Federation of Gastroenterology and took place on April 12-15, 2011, in Bento Gonçalves, RS, Brazil. Thirty-one delegates coming from the five Brazilian regions and one international guest, including gastroenterologists, pathologists, epidemiologists, and pediatricians undertook the meeting. The participants were allocated in one of the five main topics of the meeting: H pylori, functional dyspepsia and diagnosis; H pylori and gastric cancer; H pylori and other associated disorders; H pylori treatment and retreatment; and, epidemiology of H pylori infection in Brazil. The results of each subgroup were submitted to a final consensus voting to all participants. Relevant data were presented, and the quality of evidence, strength of recommendation, and level of consensus were graded. Seventy per cent and more votes were considered as acceptance for the final statement. This article presents the main recommendations and conclusions to guide Brazilian doctors involved in the management of H pylori infection.

show abstract

“…Fluoroquinolones have been suggested as alternative drug but generally the results of fluoroquinolone triple therapy was less than 90% (Gisbert and Morena, 2006;Graham and Shiotani, 2012). In addition, recent studies have demonstrated that longer duration with 14-day fluoroquinolone triple therapy provided treatment success of 95% (Miehlke et al, 2011).…”

Section: Discussionmentioning

confidence: 99%

High Efficacy of Levofloxacin-Dexlansoprazole-Based Quadruple Therapy as a First Line Treatment for Helicobacter pylori Eradication in Thailand

Prapitpaiboon¹,

Mahachai²,

Vilaichone³

2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Levofloxacin is an effective medication for second line Helicobacter pylori (H. pylori) eradication. However, limited studies have approved its use as an effective antibiotic in first line therapy. Dexlansoprazole is a new PPI and lacks of evidence in support of a role in H. pylori eradication. This study was designed to evaluate efficacy of levofloxacin-dexlansoprazole-based quadruple therapy for H. pylori eradication in Thailand. Materials and Methods: This prospective randomized control study was performed during June 2014 to December 2014. H. pylori infected gastritis patients were randomized to receive 7-or 14-day levofloxacin-dexlansoprazole based on quadruple therapy (levofloxacin 500 mg OD, dexlansoprazole 60 mg bid, clarithromycin MR 1000 mg OD, bismuth subsalicylate 1048 mg bid). CYP2C19 genotyping and antibiotic susceptibility tests were conducted for all patients. A 13C urea breath test was performed to confirm H. pylori eradication at least 4 weeks after treatment. Results: A total of 100 patients were enrolled, comprising 44 males and 56 females (mean age of 52.6 years). Eradication rate by PP analysis was 85.7% (42/49) with the 7-day regimen and 98% (48/49) with the 14-day regimen (85.7% vs 98%; p-value=0.059). ITT analysis was 84% and 96% with 7-and 14-day regimens, respectively (84% vs 96%; p-value=0.092). Antibiotic susceptibility testing demonstrated 35.1% resistance to metronidazole, 18.3% to clarithromycin, and 13.5% to levofloxacin. CYP2C19 genotyping revealed 54.1% RM, 34.7% IM and 11.2% PM. The 14-day regimen provided 100% eradication in patients with clarithromycin or dual clarithromycin and metronidazole H. pylori resistant strains. Moreover, the eradication rate was 96.6% in patients with CYP2C19 genotype RM. Conclusions: The 14-day levofloxacin-dexlansoprazole based quadruple therapy provides high H. pylori eradication regardless of CYP2C19 genotype, clarithromycin or dual clarithromycin and metronidazole resistant strains. This regimen could be use as an alternative first line therapy for H. pylori eradication in Thailand.

show abstract

Systematic review and meta‐analysis: levofloxacin‐based rescue regimens after Helicobacter pylori treatment failure

Abstract: SUMMARY BackgroundA quadruple therapy has been generally recommended as rescue regimen for Helicobacter pylori eradication failures.

Cited by 288 publications

References 38 publications

Letter: third‐line rescue therapy with levofloxacin after failure of two treatments to eradicate Helicobacter pylori infection – author's reply

Letter: third‐line rescue therapy with levofloxacin after failure of two treatments to eradicate Helicobacter pylori infection – author's reply

3rd BRAZILIAN CONSENSUS ON Helicobacter pylori

High Efficacy of Levofloxacin-Dexlansoprazole-Based Quadruple Therapy as a First Line Treatment for Helicobacter pylori Eradication in Thailand

Contact Info

Product

Resources

About